Landis John B. 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Mar 3, 2020
Insider Transaction Report
Form 4
Landis John B.
Director
Transactions
- Award
Stock Option (Right to Buy)
2020-02-28+33,500→ 33,500 totalExercise: $1.29From: 2021-02-28Exp: 2030-02-28→ Common Stock (33,500 underlying) - Award
Restricted Stock Units
2020-02-28+19,000→ 19,000 totalExercise: $0.00From: 2021-02-28→ Common Stock (19,000 underlying)
Footnotes (1)
- [F1]Will fully vest on the one-year anniversary of the grant date.